Recombinant Mouse Anti-VACV A14 Antibody (BF8) (CAT#: FAMAB-0331CQ)

Figure 1 Neutralization of VACV MV by A14 mAbs

Sucrose-gradient purified VACV mature virions were incubated with the indicated concentration of purified antibodies in the presence or absence of rabbit complement for 1 hr at 4°C. The mixture was then added to monolayers of BS-C-1 cells, and the inoculum was removed after one hour. The number of plaques that appeared after 2 days was enumerated. The number of plaques obtained under the indicated condition as the percentage to the number of plaques from untreated inoculums is shown. The average and standard deviation are from three independent inoculums.

Meng, X., Kaever, T., Yan, B., Traktman, P., Zajonc, D. M., Peters, B., ... & Xiang, Y. (2018). Characterization of murine antibody responses to vaccinia virus envelope protein A14 reveals an immunodominant antigen lacking of effective neutralization targets. Virology, 518, 284-292.

Figure 2 Protection of SCID mice from intravenous VACV challenge by anti-A14 mAbs

Groups of six SCID mice were treated with either 400 μL PBS or 400 μL of the indicated antibodies at a concentration of 0.25 mg/mL (=100 μg) on day −1. PBS/antibodies were injected at 200 μL intraperitoneal and 200 μL retro-orbitally. Then, mice were challenged with 1 x 105 PFU (200 μL) of VACV ACAM2000 by the retro-orbital route on day 0. (A) Body weights. (B) Body weight loss at day 58. (C) Survival. (D) Clinical scores over time.

Meng, X., Kaever, T., Yan, B., Traktman, P., Zajonc, D. M., Peters, B., ... & Xiang, Y. (2018). Characterization of murine antibody responses to vaccinia virus envelope protein A14 reveals an immunodominant antigen lacking of effective neutralization targets. Virology, 518, 284-292.